Migco Pharmaceuticals is focused on developing new drug therapies for the prevention and treatment of migraine headaches. Migco has clinical safety data for its lead compound MGX-008, a successful human concept trial and a clear path to market.

MGX-008 has been widely used and is well tolerated, thereby offering a potential superior first line drug option for physicians to offer migraine sufferers. For patients MGX-008 is expected to be taken daily over long periods to prevent headaches from developing, unlike most drugs which treat symptoms once an attack is underway. For insurers and funders it will give them a cost effective way to lower doctor and emergency ward visits.

Over 3 Million Go to Hospitals for Headache Relief

5 May 2011 – More than 3 million Americans went to hospital emergency rooms seeking relief from headaches and there were 81,000 hospitals admissions.  One-third of the emergency visits and two thirds of the hospital stays were for migraine headaches.

More… See earlier articles